Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars
This study suggests biosimilars and originators have similar remission, ED visits, and hospitalization in IBD. This reinforces confidence in their equivalence, improving access while supporting healthcare system sustainability.
Authors
- Luck Lukusa
- Albert Etingin
- Waqqas Afif
- Sasha Bernatsky
- Cristiano S Moura
- Beata Polewiczowska-Nowak
- Harminder Singh
- Neeraj Narula
- Yvette Leung
- Petros Zezos
- Laura E Targownik
Institutions
- Mount Sinai Hospital (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Thunder Bay Regional Health Sciences Centre (CA)
- McGill University Health Centre (CA)
- Institut de Recherche en Santé Digestive (FR)
- University of Manitoba (CA)
- McGill University (CA)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3748/wjg.v32.i9.114580
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00